Magnification and ultra-magnification endoscopic evaluation of esphageal mucosa epithelia, inflammatory cells and micro vessels in patients with reflux esophagitis bofore and after esomeprazole prescription

Magnification and ultra-magnification endoscopic evaluation of esphageal mucosa epithelia, inflammatory cells and micro vessels in patients with reflux esophagitis bofore and after esomeprazole prescription - reflux esophagitis, PPI treatment and magnification and ultra-magnification endoscopy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011641

Enrollment

Registered

2013-09-05

Start date

2013-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

reflux esophagitis

Interventions

oral administration of 20mg of esomeprazole for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: over 20 years old PS(ECOG) 0 or 1 more than WBC, 3,000/mm3; Hb, 8.0g/d; Plt, 75,000/mm3; AST, 100IU/L; ALT, 100IU/L; T-bil, 2.0mg/dL; sCr, 2.0mg/dL written informed consent

Exclusion criteria

Exclusion criteria: without cormobid severe diseases including heart, kidney and liver failure during pregnancy and/or milk feeding

Design outcomes

Primary

Measure	Time frame
magnification and ultra-magnification endoscopic findings in reflux esophagitis before and after esomeprazole treatment	—

Secondary

Measure	Time frame
alteration in magnification and ultra-magnification endoscopic findings before and after esomeprazole treatment	—

Countries

Japan

Contacts

Public ContactHajime isomoto

Nagasaki University Hospital Endoscopy

hhisomot@nagasaki-u.ac.jp095-819-7336

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026